Furthermore, we identified novel pathways that have not been reported in association with ACC, such as ERBB4, retinoic acid receptor, GPCR, and PDGFR signaling, that are genetically altered and are potentially targetable with currently available drugs. Here, PDGFRB is linked to adrenal cortex carcinoma.